Published in Health and Medicine Week, December 6th, 2004
The Phase Ib clinical trial will evaluate the safety of the combination and determine an appropriate dose and schedule for the use of KOS-953 in combination with Velcade. Dr. Asher Chanan-Khan, principal investigator at Roswell Park Cancer Center, was the first site to begin enrollment; additional centers will include Dana Farber Cancer Center, H. Lee Moffitt Cancer Center and Arizona Cancer Center.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.